Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC-Reference-Cited by-同舟云学术

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Published:2019-05-28 Issue:1 Volume:38 Page:
ISSN:1756-9966
Container-title:Journal of Experimental & Clinical Cancer Research
language:en
Short-container-title:J Exp Clin Cancer Res

Author:

La Monica Silvia,Minari Roberta,Cretella Daniele,Flammini Lisa,Fumarola Claudia,Bonelli Mara,Cavazzoni Andrea,Digiacomo Graziana,Galetti Maricla,Madeddu Denise,Falco Angela,Lagrasta Costanza Annamaria,Squadrilli Anna,Barocelli Elisabetta,Romanel Alessandro,Quaini Federico,Petronini Pier Giorgio,Tiseo Marcello,Alfieri Roberta^ORCID

Funder

Associazione Italiana Ricerca sul Cancro

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13046-019-1240-x.pdf

Reference30 articles.

1. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.

2. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al. Osimertinib or platinum-Pemetrexed in EGFR T790M-positive lung Cancer. N Engl J Med. 2017;376:629–40.